Form 4: Alnylam Director Carolyn R. Bertozzi Acquires Stock Options

Director Carolyn R. Bertozzi acquired 5,228 stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Summary

• On May 16, 2024, Carolyn R. Bertozzi, a director of Alnylam Pharmaceuticals, Inc., acquired 5,228 stock options.
• The exercise price of these options is $151.22.
• The options vest in full on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
• The options expire on May 16, 2034.
• Following the transaction, Bertozzi directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The document is a neutral report of an insider transaction. The sentiment is moderately positive as it reflects an investment by a director in the company's stock, but it's a routine filing.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are typical for stock option grants.
• Comparing the size of the grant to those of directors at comparable companies (e.g., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals) would provide further context.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates